204.55
-0.08880549(-0.04%)
Currency In USD
Address
700 US Highway 202/206
Bridgewater, NJ 08807
United States of America
Phone
908 977 9900
Website
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
1271
First IPO Date
January 29, 2018
| Name | Title | Pay | Year Born |
| Mr. William H. Lewis J.D., M.B.A. | President, Chief Executive Officer & Chairman | 2.12M | 1969 |
| Ms. S. Nicole Schaeffer M.B.A. | Chief People Strategy Officer | 660,810 | 1968 |
| Ms. Sara M. Bonstein M.B.A. | Chief Financial Officer | 1.01M | 1981 |
| Mr. John Drayton Wise M.B.A. | Consultant | 1.11M | 1975 |
| Dr. Martina Flammer M.B.A., M.D. | Chief Medical Officer | 1.11M | 1964 |
| Mr. Roger Adsett M.B.A. | Chief Operating Officer | 1.26M | 1969 |
| Mr. Brian K. Kaspar Ph.D. | Chief Scientific Officer | 0 | 1974 |
| Bryan Dunn | Vice President of Investor Relations | 0 | N/A |
| Mr. Michael Alexander Smith J.D. | Chief Legal Officer & Corporate Secretary | 0 | 1977 |
| Ms. Claire Mulhearn | Vice President of Corporate Communications | 0 | N/A |
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.